Business Description
Psyence Biomedical Ltd
NAICS : 541710
SIC : 3741
ISIN : CA74449F1009
Total Employee Number:
12Description
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.97 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 77.3 | |||||
3-Year EPS without NRI Growth Rate | 77.6 | |||||
3-Year FCF Growth Rate | 69.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 66.73 | |||||
9-Day RSI | 57.92 | |||||
14-Day RSI | 50.92 | |||||
3-1 Month Momentum % | -54.24 | |||||
6-1 Month Momentum % | -38.29 | |||||
12-1 Month Momentum % | -94.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.62 | |||||
Quick Ratio | 14.62 | |||||
Cash Ratio | 11.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -814.3 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -58.56 | |||||
ROA % | -55.2 | |||||
ROIC % | -107.25 | |||||
ROC (Joel Greenblatt) % | -2943.48 | |||||
ROCE % | -58.48 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.43 | |||||
Price-to-Tangible-Book | 0.43 | |||||
EV-to-EBIT | -1.82 | |||||
EV-to-EBITDA | -1.82 | |||||
EV-to-FCF | -1.55 | |||||
| Price-to-Net-Current-Asset-Value | 0.85 | |||||
| Price-to-Net-Cash | 1.06 | |||||
Earnings Yield (Greenblatt) % | -54.95 | |||||
FCF Yield % | -67.55 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PBM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Psyence Biomedical Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -12.56 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 205.1 | ||
| 14-Day RSI | 50.92 | ||
| 14-Day ATR ($) | 0.25172 | ||
| 20-Day SMA ($) | 3.003 | ||
| 12-1 Month Momentum % | -94.81 | ||
| 52-Week Range ($) | 1.92 - 59.375 | ||
| Shares Outstanding (Mil) | 3.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Psyence Biomedical Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Psyence Biomedical Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-06-22 | 3.15 (+2.27%) | ||
| General meeting for 2026 | 2026-05-19 09:00 | 4.61 (-3.35%) | ||
| 0.16:1 Stock Split | 2026-02-02 | 4.00 (-7.65%) | ||
| Annual report for 2025 | 2025-06-25 | 31.58 (+4.38%) | ||
| General meeting for 2024 | 2025-06-07 | 34.50 (+8.23%) | ||
| 0.125471:1 Stock Split | 2025-05-05 | 21.62 (-0.18%) | ||
| 0.0133333:1 Stock Split | 2024-11-26 | 178.95 (+8.86%) |
Show
Entries
Psyence Biomedical Ltd Frequently Asked Questions
What is Psyence Biomedical Ltd(PBM)'s stock price today?
The current price of PBM is $3.16. The 52 week high of PBM is $59.38 and 52 week low is $1.92.
When is next earnings date of Psyence Biomedical Ltd(PBM)?
The next earnings date of Psyence Biomedical Ltd(PBM) is .
Does Psyence Biomedical Ltd(PBM) pay dividends? If so, how much?
Psyence Biomedical Ltd(PBM) does not pay dividend.
Guru Commentaries on NAS:PBM
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus? | 2024-02-12 |
Articles on Psyence Biomedical Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers